Cargando…

Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis

For more than a year now, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been causing the coronavirus disease (COVID-19) pandemic with high mortality and detrimental effects on society, economy, and individual lives. Great hopes are being placed on vaccination as one of the most po...

Descripción completa

Detalles Bibliográficos
Autores principales:	Woopen, Christina, Schleußner, Katharina, Akgün, Katja, Ziemssen, Tjalf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256163/ https://www.ncbi.nlm.nih.gov/pubmed/34234787 http://dx.doi.org/10.3389/fimmu.2021.701752

Ejemplares similares

Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses
por: Woopen, Christina, et al.
Publicado: (2022)

NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines
por: Mueller-Enz, Magdalena, et al.
Publicado: (2023)

Timing of SARS-CoV-2 Vaccination Matters in People With Multiple Sclerosis on Pulsed Anti-CD20 Treatment
por: Woopen, Christina, et al.
Publicado: (2022)

Long-Term Immune Response Profiles to SARS-CoV-2 Vaccination and Infection in People with Multiple Sclerosis on Anti-CD20 Therapy
por: Woopen, Christina, et al.
Publicado: (2023)

Digital Twins for Multiple Sclerosis
por: Voigt, Isabel, et al.
Publicado: (2021)

Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis
por: Akgün, Katja, et al.
Publicado: (2020)

Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation
por: Proschmann, Undine, et al.
Publicado: (2021)

Differential effects of selective versus unselective sphingosine 1-phosphate receptor modulators on T- and B-cell response to SARS-CoV-2 vaccination
por: Proschmann, Undine, et al.
Publicado: (2023)

Molecular biomarkers in multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

The need for a strategic therapeutic approach: multiple sclerosis in check
por: Inojosa, Hernan, et al.
Publicado: (2022)

Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients
por: Akgün, Katja, et al.
Publicado: (2022)

Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis
por: Proschmann, Undine, et al.
Publicado: (2021)

Results on SARS-CoV-2 mRNA Vaccine Booster from an Open-Label Multicenter Study in Ofatumumab-Treated Participants with Relapsing Multiple Sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2023)

Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects
por: Fischer, Stefanie, et al.
Publicado: (2021)

Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

S1P receptor modulators and the cardiovascular autonomic nervous system in multiple sclerosis: a narrative review
por: Constantinescu, Victor, et al.
Publicado: (2022)

Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis
por: Akgün, Katja, et al.
Publicado: (2018)

Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started?
por: Bellucci, Gianmarco, et al.
Publicado: (2021)

SARS-CoV-2 and Multiple Sclerosis: Potential for Disease Exacerbation
por: MacDougall, Madison, et al.
Publicado: (2022)

Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccination
por: Faissner, Simon, et al.
Publicado: (2022)

Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in
por: Pugliatti, Maura, et al.
Publicado: (2022)

Ella versus Simoa Serum Neurofilament Assessment to Monitor Treatment Response in Highly Active Multiple Sclerosis Patients
por: Nötzel, Martin, et al.
Publicado: (2022)

Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients
por: Kaufmann, Maxi, et al.
Publicado: (2018)

Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies
por: Akgün, Katja, et al.
Publicado: (2019)

Designing an Electronic Patient Management System for Multiple Sclerosis: Building a Next Generation Multiple Sclerosis Documentation System
por: Kern, Raimar, et al.
Publicado: (2016)

Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up
por: Kaufmann, Maxi, et al.
Publicado: (2018)

Can ChatGPT explain it? Use of artificial intelligence in multiple sclerosis communication
por: Inojosa, Hernan, et al.
Publicado: (2023)

Data Collection in Multiple Sclerosis: The MSDS Approach
por: Ziemssen, Tjalf, et al.
Publicado: (2020)

Influence of exercise on quantity and deformability of immune cells in multiple sclerosis
por: Proschmann, Undine, et al.
Publicado: (2023)

No Impact of Long-Term Fingolimod Treatment on Fecal Secretory Immunoglobulin A Levels in Patients With Multiple Sclerosis
por: Inojosa, Hernan, et al.
Publicado: (2020)

Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions
por: Cohen, Jeffrey A, et al.
Publicado: (2022)

Immune response to SARS-CoV-2 mRNA vaccination in multiple sclerosis patients after rituximab treatment interruption
por: Gröning, Remigius, et al.
Publicado: (2023)

Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Digital Biomarkers in Multiple Sclerosis
por: Dillenseger, Anja, et al.
Publicado: (2021)

Digital Innovation in Multiple Sclerosis Management
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis
por: Li, Kai, et al.
Publicado: (2017)

CNS inflammation after natalizumab therapy for multiple sclerosis: A retrospective histopathological and CSF cohort study
por: Häusler, Darius, et al.
Publicado: (2021)

Assessing the immune response to SARS-CoV-2 mRNA vaccines in siponimod-treated patients: a nonrandomized controlled clinical trial (AMA-VACC)
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting
por: Rodriguez-Leal, Francisco Alejandro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5ilqo4offodcah18c2vc7eo1hu